E-therapeutics Plc
ETXPFOTCHealthcare
$0.13
+$0.00(+0.00%)
Market Cap$75963547
P/E Ratio—
52W High$0.13
52W Low$0.13
E-therapeutics Plc (ETXPF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ETXPF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-01 | 2024-01 | 2023-01 | 2022-01 | 2021-01 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | 100.00% | 100.00% | 74.37% | 72.82% |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.01B | $0.01B | $0.01B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.02B | $0.01B | $0.01B | $0.01B | $0.01B |
| Operating Income | ($0.02B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.02B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Income Tax Expense | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Income | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.02 | $-0.02 | $-0.02 | $-0.02 | $-0.01 |
| Wtd Avg Shares | 0.74B | 0.58B | 0.54B | 0.49B | 0.37B |
| EBITDA | ($0.02B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.00B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · GBP · B
Explore more E-therapeutics Plc data
About E-therapeutics Plc (ETXPF) Income Statement
E-therapeutics Plc (ETXPF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ETXPF reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.01B) — a net profit margin of —.
Frequently asked questions
ETXPF · 4 questionsE-therapeutics Plc (ETXPF) reported revenue of $0.00B for 2025, down 100.0% year-over-year.
ETXPF revenueETXPF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09